Literature DB >> 1691479

Oncogenicity of the ret transforming gene in MMTV/ret transgenic mice.

T Iwamoto1, M Takahashi, M Ito, M Hamaguchi, K Isobe, N Misawa, J Asai, T Yoshida, I Nakashima.   

Abstract

We have successfully produced transgenic mice that carry the ret oncogene driven by a mouse mammary tumor virus promoter/enhancer. Mammary and salivary gland adenocarcinomas were developed in a stochastic fashion in these mice. Moreover, premalignant tumors with hyperplastic and dysplastic lesions of Harderian glands and male reproductive tracts frequently occurred at young ages. High expression of the transgene was closely associated with the development of these tumors although the levels of the transgene expression were variable among individuals. In addition, large amounts of phosphotyrosine-containing proteins were detected in cell lysates from mammary and salivary adenocarcinomas by immunoblotting with the anti-phosphotyrosine antibody.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1691479

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  11 in total

Review 1.  Expression of activated oncogenes in the murine mammary gland: transgenic models for human breast cancer.

Authors:  W J Muller
Journal:  Cancer Metastasis Rev       Date:  1991-10       Impact factor: 9.264

2.  Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and RET and creating the oncogenic sequence RET/PTC.

Authors:  M A Pierotti; M Santoro; R B Jenkins; G Sozzi; I Bongarzone; M Grieco; N Monzini; M Miozzo; M A Herrmann; A Fusco
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

Review 3.  Genetically engineered mouse models of mammary intraepithelial neoplasia.

Authors:  R D Cardiff; D Moghanaki; R A Jensen
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-10       Impact factor: 2.673

Review 4.  Genetically modified laboratory mice with sebaceous glands abnormalities.

Authors:  Carmen Ehrmann; Marlon R Schneider
Journal:  Cell Mol Life Sci       Date:  2016-07-25       Impact factor: 9.261

5.  Chronic expression of wild-type Ret receptor in the mammary gland induces luminal tumors that are sensitive to Ret inhibition.

Authors:  Albana Gattelli; Martín E García Solá; Tim C Roloff; Robert D Cardiff; Edith C Kordon; Lewis A Chodosh; Nancy E Hynes
Journal:  Oncogene       Date:  2018-04-26       Impact factor: 9.867

Review 6.  Ret Receptor Has Distinct Alterations and Functions in Breast Cancer.

Authors:  Albana Gattelli; Nancy E Hynes; Ignacio E Schor; Sabrina A Vallone
Journal:  J Mammary Gland Biol Neoplasia       Date:  2020-02-21       Impact factor: 2.673

7.  Forced expression of miR-143 represses ERK5/c-Myc and p68/p72 signaling in concert with miR-145 in gut tumors of Apc(Min) mice.

Authors:  Yuji Takaoka; Yuko Shimizu; Hitoki Hasegawa; Yasuo Ouchi; Shanlou Qiao; Miki Nagahara; Masatoshi Ichihara; Jiing-Dwan Lee; Koichi Adachi; Michinari Hamaguchi; Takashi Iwamoto
Journal:  PLoS One       Date:  2012-08-02       Impact factor: 3.240

8.  Aberrant melanogenesis and melanocytic tumour development in transgenic mice that carry a metallothionein/ret fusion gene.

Authors:  T Iwamoto; M Takahashi; M Ito; K Hamatani; M Ohbayashi; W Wajjwalku; K Isobe; I Nakashima
Journal:  EMBO J       Date:  1991-11       Impact factor: 11.598

9.  An activated allele of the c-erbB-2 oncogene impairs kidney and lung function and causes early death of transgenic mice.

Authors:  E Stöcklin; F Botteri; B Groner
Journal:  J Cell Biol       Date:  1993-07       Impact factor: 10.539

10.  Involvement of RET oncogene in human tumours: specificity of RET activation to thyroid tumours.

Authors:  M Santoro; N Sabino; Y Ishizaka; T Ushijima; F Carlomagno; A Cerrato; M Grieco; C Battaglia; M L Martelli; C Paulin
Journal:  Br J Cancer       Date:  1993-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.